{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T22:12:34Z","timestamp":1769724754218,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.therap.2024.05.006","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T16:34:15Z","timestamp":1717605255000},"page":"709-717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacog\u00e9n\u00e9tique de l\u2019ototoxicit\u00e9 des aminosides\u00a0: \u00e9tat des connaissances et des pratiques\u00a0\u2013\u00a0recommandations du R\u00e9seau francophone de pharmacog\u00e9n\u00e9tique (RNPGx)"],"prefix":"10.1016","volume":"79","author":[{"given":"Louis","family":"Lebreton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Hennart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Baklouti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lien","family":"Trimouille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Becquemont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire-Marie","family":"Dhaenens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Picard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2024.05.006_bib0220","series-title":"Suivi th\u00e9rapeutique pharmacologique des aminosides\u00a0: amikacine, gentamicine, tobramycine\u00a0\u2013\u00a0EM consulte. Biologie m\u00e9dicale","author":"Bourguignon","year":"2015"},{"key":"10.1016\/j.therap.2024.05.006_bib0225","series-title":"Actualit\u00e9\u00a0\u2013\u00a0bon usage des aminosides administr\u00e9s par voie injectable\u00a0: gentamicine, tobramycine, n\u00e9tilmicine, amikacine","year":"2021"},{"key":"10.1016\/j.therap.2024.05.006_bib0230","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2515\/therapie\/2011001","article-title":"Niveau de preuve du suivi th\u00e9rapeutique pharmacologique des aminosides","volume":"66","author":"Venisse","year":"2011","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.05.006_bib0235","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/0897190014546836","article-title":"Aminoglycoside-induced nephrotoxicity","volume":"27","author":"Wargo","year":"2014","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.therap.2024.05.006_bib0240","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1126\/science.103.2673.355","article-title":"Studies on the toxicity of streptomycin for man: a preliminary report","volume":"103","author":"Hettig","year":"1946","journal-title":"Science"},{"key":"10.1016\/j.therap.2024.05.006_bib0245","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/jac\/37.4.645","article-title":"A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses","volume":"37","author":"Munckhof","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.therap.2024.05.006_bib0250","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00129492-200407000-00025","article-title":"Permanent gentamicin vestibulotoxicity","volume":"25","author":"Black","year":"2004","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.therap.2024.05.006_bib0255","first-page":"937861","article-title":"Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection","volume":"2011","author":"Huth","year":"2011","journal-title":"Int J Otolaryngol"},{"key":"10.1016\/j.therap.2024.05.006_bib0260","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/nm1296-1338","article-title":"N-methyl-D-aspartate antagonists limit aminoglycoside antibiotic-induced hearing loss","volume":"2","author":"Basile","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.therap.2024.05.006_bib0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1117\/1.JBO.24.5.051403","article-title":"Aminoglycosides rapidly inhibit NAD(P)H metabolism increasing reactive oxygen species and cochlear cell demise","volume":"24","author":"Desa","year":"2018","journal-title":"J Biomed Opt"},{"key":"10.1016\/j.therap.2024.05.006_bib0270","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/jmg.28.2.79","article-title":"Genetic aspects of antibiotic induced deafness: mitochondrial inheritance","volume":"28","author":"Hu","year":"1991","journal-title":"J Med Genet"},{"key":"10.1016\/j.therap.2024.05.006_bib0275","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.therap.2016.09.007","article-title":"Traitements personnalis\u00e9s gr\u00e2ce \u00e0 la pharmacog\u00e9n\u00e9tique: niveaux de preuve et de recommandations du R\u00e9seau national de pharmacog\u00e9n\u00e9tique (RNPGx)","volume":"72","author":"Picard","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.05.006_bib0280","series-title":"GeneReviews\u00ae [Internet]","article-title":"Nonsyndromic hearing loss and deafness, mitochondrial, 2004\u00a0Oct 22 [updated 2018\u00a0Jun 14]","author":"Usami","year":"1993"},{"key":"10.1016\/j.therap.2024.05.006_bib0285","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1093\/nar\/21.18.4174","article-title":"A molecular basis for human hypersensitivity to aminoglycoside antibiotics","volume":"21","author":"Hutchin","year":"1993","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.therap.2024.05.006_bib0290","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cpt.2350","article-title":"An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine","volume":"110","author":"Whirl-Carrillo","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2024.05.006_bib0295","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456\u00a0humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.therap.2024.05.006_bib0300","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/jmedgenet-2014-102753","article-title":"Mitochondrial mutations associated with aminoglycoside ototoxicity and hearing loss susceptibility identified by meta-analysis","volume":"52","author":"Jing","year":"2015","journal-title":"J Med Genet"},{"key":"10.1016\/j.therap.2024.05.006_bib0305","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.mito.2010.01.007","article-title":"Mitochondrial 12S rRNA variants in 1642\u00a0Han Chinese pediatric subjects with aminoglycoside-induced and nonsyndromic hearing loss","volume":"10","author":"Lu","year":"2010","journal-title":"Mithochondrion"},{"key":"10.1016\/j.therap.2024.05.006_bib0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.joto.2017.02.001","article-title":"Mitochondrial DNA mutations associated with aminoglycoside induced ototoxicity","volume":"12","author":"Gao","year":"2017","journal-title":"J Otol"},{"key":"10.1016\/j.therap.2024.05.006_bib0315","doi-asserted-by":"crossref","first-page":"20888","DOI":"10.1073\/pnas.0811258106","article-title":"Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity","volume":"105","author":"Hobbie","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.therap.2024.05.006_bib0320","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/jmg.40.8.632","article-title":"Heteroplasmy for the 1555A>G mutation in the mitochondrial 12S rRNA gene in six Spanish families with non-syndromic hearing loss","volume":"40","author":"del Castillo","year":"2003","journal-title":"J Med Genet"},{"key":"10.1016\/j.therap.2024.05.006_bib0325","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/humu.20639","article-title":"Detection of unrecognized low-level mtDNA heteroplasmy may explain the variable phenotypic expressivity of apparently homoplasmic mtDNA mutations","volume":"29","author":"Ballana","year":"2008","journal-title":"Hum Mutat"},{"key":"10.1016\/j.therap.2024.05.006_bib0330","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.mito.2009.07.006","article-title":"Mitochondrial haplotype and phenotype of 13\u00a0Chinese families may suggest multi-original evolution of mitochondrial C1494T mutation","volume":"9","author":"Zhu","year":"2009","journal-title":"Mitochondrion"},{"key":"10.1016\/j.therap.2024.05.006_bib0335","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/jmedgenet-2014-102753","article-title":"Mitochondrial mutations associated with aminoglycoside ototoxicity and hearing loss susceptibility identified by meta-analysis","volume":"52","author":"Jing","year":"2015","journal-title":"J Med Genet"},{"key":"10.1016\/j.therap.2024.05.006_bib0340","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1479-5876-9-4","article-title":"Frequency and spectrum of mitochondrial 12S rRNA variants in 440\u00a0Han Chinese hearing impaired pediatric subjects from two otology clinics","volume":"9","author":"Shen","year":"2011","journal-title":"J Transl Med"},{"key":"10.1016\/j.therap.2024.05.006_bib0345","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bbrc.2006.07.031","article-title":"Extremely low penetrance of deafness associated with the mitochondrial 12S rRNA T1095C mutation in three Chinese families","volume":"348","author":"Dai","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.therap.2024.05.006_bib0350","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/sj.ejhg.5200601","article-title":"Maternally inherited deafness associated with a T1095C mutation in the mDNA","volume":"9","author":"Tessa","year":"2001","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.therap.2024.05.006_bib0355","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.mito.2012.06.006","article-title":"The mitochondrial T1095C mutation increases gentamicin-mediated apoptosis","volume":"12","author":"Muyderman","year":"2012","journal-title":"Mitochondrion"},{"key":"10.1016\/j.therap.2024.05.006_bib0360","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.bbrc.2008.01.143","article-title":"A mutation in mitochondrial 12S rRNA, A827G, in Argentinean family with hearing loss after aminoglycoside treatment","volume":"368","author":"Chaig","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.therap.2024.05.006_bib0365","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.bbrc.2006.05.208","article-title":"Mitochondrial 12S rRNA A827G mutation is involved in the genetic susceptibility to aminoglycoside ototoxicity","volume":"346","author":"Xing","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.therap.2024.05.006_bib0370","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00008571-199506000-00005","article-title":"Susceptibility mutations in the mitochondrial small ribosomal RNA gene in aminoglycoside induced deafness","volume":"5","author":"Bacino","year":"1995","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.therap.2024.05.006_bib0375","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1590\/S1808-86942011000500006","article-title":"mtDNA mutations, hearing loss and aminoglycoside treatment in Mexicans","volume":"77","author":"Meza","year":"2011","journal-title":"Braz J Otorhinolaryngol"},{"key":"10.1016\/j.therap.2024.05.006_bib0380","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/00005537-199704000-00011","article-title":"Genetic and clinical features of sensorineural hearing loss associated with the 1555\u00a0mitochondrial mutation","volume":"107","author":"Usami","year":"1997","journal-title":"Laryngoscope"},{"key":"10.1016\/j.therap.2024.05.006_bib0385","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.ijporl.2015.04.028","article-title":"Rapid identification of aminoglycoside-induced deafness gene mutations using multiplex real-time polymerase chain reaction","volume":"79","author":"Huang","year":"2015","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"10.1016\/j.therap.2024.05.006_bib0390","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/sj.ejhg.5201891","article-title":"Whole mitochondrial genome screening in maternally inherited non-syndromic hearing impairment using a microarray resequencing mitochondrial DNA chip","volume":"15","author":"L\u00e9v\u00eaque","year":"2007","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.therap.2024.05.006_bib0395","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jmoldx.2021.03.002","article-title":"Current and new next-generation sequencing approaches to study mitochondrial DNA","volume":"23","author":"Legati","year":"2021","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.therap.2024.05.006_bib0400","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.3390\/jcm9072082","article-title":"A novel approach for the identification of pharmacogenetic variants in MT-RNR1\u00a0through next-generation sequencing off-target data","volume":"9","author":"Lanillos","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.therap.2024.05.006_bib0405","series-title":"Overview\u00a0|\u00a0Genedrive MT-RNR1\u00a0ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies: early value assessment\u00a0|\u00a0Guidance\u00a0|\u00a0NICE","year":"2023"},{"key":"10.1016\/j.therap.2024.05.006_bib0410","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jamapediatrics.2022.0187","article-title":"Rapid point-of-care genotyping to avoid aminoglycoside-induced ototoxicity in neonatal intensive care","volume":"176","author":"McDermott","year":"2022","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.therap.2024.05.006_bib0415","series-title":"Tuberculose en France\u00a0: les chiffres 2020","year":"2021"},{"key":"10.1016\/j.therap.2024.05.006_bib0420","series-title":"Mucoviscidose\u00a0: des pistes pour la sant\u00e9 encourageantes","year":"2021"},{"key":"10.1016\/j.therap.2024.05.006_bib0425","series-title":"Principaux r\u00e9sultats de l\u2019enqu\u00eate nationale de pr\u00e9valence 2022\u00a0des infections nosocomiales et des traitements anti-infectieux en \u00e9tablissement de sant\u00e9","year":"2023"},{"key":"10.1016\/j.therap.2024.05.006_bib0215","series-title":"Mise au point sur le bon usage des aminosides administr\u00e9s par voie injectable. Gentamicine, tobramycine, n\u00e9tilmicine, amikacine. Propri\u00e9t\u00e9s pharmacologiques, indications, posologies et modes d\u2019administration, surveillance du traitement. Messages cl\u00e9s","year":"2011"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724000684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724000684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T13:55:15Z","timestamp":1732370115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595724000684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0040595724000684"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2024.05.006","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacog\u00e9n\u00e9tique de l\u2019ototoxicit\u00e9 des aminosides\u00a0: \u00e9tat des connaissances et des pratiques\u00a0\u2013\u00a0recommandations du R\u00e9seau francophone de pharmacog\u00e9n\u00e9tique (RNPGx)","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2024.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}